Sagent Pharmaceuticals Announces the Launch of Colistimethate for Injection, USP

SCHAUMBURG, Ill., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Colistimethate for Injection, USP, an anti-infective, in a preservative-free glass vial. According to IMS, for the 12 months ending October 2014, the US market for Colistimethate approximated $12 million. As with all products in Sagent's portfolio, Colistimethate features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

About Colistimethate for Injection, USP

Colistimethate for injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.

The package insert, available at, contains the indications, complete side effect profile and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 jsinger@sagentpharma.comSource:Sagent Pharmaceuticals, Inc.